Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment

NCT06361823 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can safely lower high pressure inside the skull in adults with idiopathic intracranial hypertension.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 74 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2024-05 · est. completion 2025-01

What this study is testing ClinicalTrials.gov NCT06361823 ↗

Description as written by the study sponsor.

This study aims to investigate the safety and efficacy of semaglutide in patients with Idiopathic intracranial hypertension.

Treatments tested

Semaglutide also known as Ozempic Drug

Giving Semaglutide via subcutaneous injections on a weekly basis for a duration of 3 months. The dosage is 0.25 mg for the initial month, then upped to 0.5 mg for patients who could handle it in the second month, and eventually escalated to 1.0 mg for patients who continued to tolerate it in the third month.
Low calorie diet Dietary supplement

Low calorie diet (max 1200 kcal/day)

Main thing measured	Intracranial pressure
Sponsor	Capital Medical University
Conditions studied	Idiopathic Intracranial Hypertension
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06361823 ↗